New aliases are not short since risk of good news is high. They just want to buy cheaper shares.
IMHO the new aliases being created on an almost daily basis just to bash NVIV are not short sellers. There is too great of a risk of news forthcoming regarding the start of clinical trials, or more TV coverage or high-profile financial media coverage. This is just the usual wanna-be longs looking to start a new position or add to existing positions.
These folks are just trying to create temporarily weak sentiment in the hopes of grabbing cheaper shares.
The strategy backfires because many eyes are on this stock and a lot of folks would like to do the same thing and add on any dip. So anytime price drops below the 3.15 range even for a few minutes, there are an abundance of buyers ready to grab shares.
Ignore the arguments based on dilution. NVIV is well funded to complete clinical trials on their biopolymer scaffold without cash infusion.